Reforms at the FDA Level
In response to internal FDA reforms, Molly Burich, MS; Amanda Forys, MSPH; Ha Kung Wong, JD; and Angus Worthing, MD, FACR, FACP, share their expectations concerning review and approval timelines for biosimilar products that are safe, effective, and priced competitively within the market.
November 14, 2017
View Text Version